The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective analysis of tarlatamab outcomes and safety in a global multicenter electronic health record network (TriNetX) database.
 
Mostafa Eysha
No Relationships to Disclose
 
Bayan Khasawneh
No Relationships to Disclose
 
Islam Hamza Zaki
No Relationships to Disclose
 
Kaiwen Wang
Consulting or Advisory Role - Bayer; Janssen Oncology; Pfizer
 
Frank Fossella
No Relationships to Disclose
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline; InSightec; Lyell Immunopharma; Regeneron
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); BioNTech SE; Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Henlius; Jounce Therapeutics (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer; Shattuck Labs (Inst); verismo (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - Hengenix; Nanobiotix (Inst)
 
Nagla Abdel Karim
No Relationships to Disclose
 
Carl Gay
Honoraria - American Society for Radiation Oncology; Amgen; Aptitude Health; AstraZeneca; Daiichi Sankyo Nordics; DAVA Pharmaceuticals; Peerview; Physicans' Education Resource; Targeted Oncology
Consulting or Advisory Role - Abdera Therapeutics; Amgen; AstraZeneca; BeOne; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daiichi Sankyo Nordics; G1 Therapeutics; Jazz Pharmaceuticals; Monte Rosa Therapeutics; Pharmacosmos; Pharmerit
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - US-20240011103-A1 MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES
Travel, Accommodations, Expenses - American Society for Radiation Oncology; AstraZeneca; Dava Oncology; ESMO; ETOP; IASLC; Jazz Pharmaceuticals; MJH Live Events; Roche/Genentech
 
Lauren Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Novartis; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas (Priority date: 3/3/2021); Molecular subtyping of small cell lung cancer to predict therapeutic responses (US Patent No.: 11,732,306; Priority Date 9/3/2019; Issue Date 8/22/2023)
 
Bingnan Zhang
Honoraria - Dava Oncology; IDEOlogy Health
Consulting or Advisory Role - Abdera Thereapeutics; Oncohost